Prevalence of comorbid major depressive disorder in Type 2 diabetes: a meta-analysis of comparative and epidemiological studies
Expert Commentary and Research Insights GLP-1 Therapy Backed by Clinical Studies Brello Health's treatment approach is built on the growing body of evidence supporting GLP-1 receptor agonists, such as semaglutide and tirzepatide, for weight management
Compared with placebo, the smallest percentage body-weight loss was observed in individuals with type 2 diabetes, with an estimated treatment difference of 6.2% after 68 weeks of treatment [35], whereas an additional body-weight loss of 10.312.5% after 68 weeks of treatment (without prior run-in with semaglutide) was observed in individuals without diabetes in trials aiming to directly compare semaglutide with placebo [26, 36, 38, 39] (Fig
doi:10.3233/JAD-220180 Ning P, Luo A, Mu X, Xu Y, Li T
Material Limitations of This Review
Glucose transporters: Physiological and pathological roles
